Palumbo Wealth Management LLC Purchases 9,695 Shares of Exagen Inc. (NASDAQ:XGN)

Palumbo Wealth Management LLC boosted its position in Exagen Inc. (NASDAQ:XGN) by 14.5% during the third quarter, HoldingsChannel reports. The fund owned 76,364 shares of the company’s stock after buying an additional 9,695 shares during the quarter. Palumbo Wealth Management LLC’s holdings in Exagen were worth $236,000 as of its most recent filing with the SEC.

Separately, Creative Planning purchased a new position in Exagen during the 3rd quarter valued at about $110,000. 75.25% of the stock is owned by institutional investors.

Exagen Price Performance

XGN stock traded up $0.08 during mid-day trading on Thursday, reaching $2.59. 970 shares of the company traded hands, compared to its average volume of 42,443. The company has a debt-to-equity ratio of 1.13, a current ratio of 4.32 and a quick ratio of 4.32. The company has a market capitalization of $45.03 million, a P/E ratio of -2.59 and a beta of 1.32. Exagen Inc. has a 52-week low of $1.30 and a 52-week high of $3.71. The company has a fifty day moving average price of $2.90 and a 200-day moving average price of $2.28.

Exagen (NASDAQ:XGN) last posted its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.20. The business had revenue of $15.06 million during the quarter, compared to analyst estimates of $13.20 million. Exagen had a negative return on equity of 78.90% and a negative net margin of 30.56%. During the same quarter in the previous year, the firm earned ($0.28) EPS. As a group, analysts anticipate that Exagen Inc. will post -1.02 earnings per share for the current year.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).